Print this page    •   Back to Web version of article

Natural History, Clinical Manifestations, and Prognostic Indicators of Disease Progression and Survival of Hepatitis C Virus (HCV) Infection

By Michael Marco

July 9-14, 2000

The most accurate means of determining the entire spectrum of outcomes of HCV infection would be to identify a large cohort at a time of initial infection; to select a carefully matched seronegative control group who, like the seropositive group, could be maintained under active surveillance for periods of 30 years or more; and to omit therapy that might alter outcome and hence modify natural history. Obviously, these conditions cannot be met and, therefore, the desired information may never be forthcoming.
-- Leonard Seeff, The Natural History of Hepatitis C -- A Quandary


Introduction

Numerous HCV natural history studies have attempted to detail the course of HCV infection, yet most have been unable able to chart disease progression from initial infection to end-stage disease, and only one has more than 25 years of follow-up (Seeff 2000b). Long-term, accurate natural history data are needed to better understand the pathogenesis of the disease and to determine which patients need treatment now, which ones can wait for more effective treatment, and which ones will probably never need treatment.


Clinical Features and Outcome of Acute HCV

Acute HCV infection most often exhibits no clinical symptoms: 60% to 75% of individual are asymptomatic; 20% to 30% become jaundiced; and 10% to 20% have symptoms including fatigue, nausea, and vomiting (Dienstag 1983; Aach 1991; Koretz 1993). In those who develop jaundice, peak bilirubin levels are usually less than 12 mg/dl (mean: 8.4 mg/dl) and levels appear to resolve in less than four weeks (Esteban 1999). Fulminant hepatic failure with primary HCV infection is extremely rare.

Approximately 20% of newly individuals have symptoms that arise before the seroconversion to anti-HCV occurs (antibody-positive) (Koretz 1993). The average time from exposure to seroconversion is approximately 50 days, although it can be as long as nine months (Tremolada 1991; MJ Alter 1992).

During acute infection, a person's aminotransferase (ALT) levels (liver enzymes) rise to 200­600 IU/I, but in 20% of cases, peak ALT levels exceed 1000 IU/l (Esteban 1999). There is often an episodic, fluctuating pattern of ALT levels during the first few months, where levels flare to a 10- to 15-fold increase. Approximately 25% of patients develop a sustained plateau pattern where ALT levels remain below 450 IU/l for many months. In others, ALT level can normalize (suggesting recovery), yet flare up again within months to years. This pattern is a tell-tale sign of chronic infection with HCV and indicates a need for ongoing ALT monitoring (MJ Alter 1992; Esteban 1999). More than 12 months after acute infection, ALT levels will continue to be elevated in about 60% of individuals (Esteban 1998).

Continued normalization of ALT levels -- termed "biochemical recovery" -- does not always mean a loss of anti-HCV or absence of HCV RNA (MJ Alter 1992). Likewise, continued abnormal ALT levels with anti-HCV positivity does not necessarily mean that a person is chronically infected with HCV. Fifteen to twenty-five percent of acutely HCV-infected individuals will clear their infections (Shakil 1995). Complete resolution of HCV infection is defined as both the absence of HCV RNA in serum and a normalization of serum ALT level. Shakil and colleagues from the National Institutes of Health (NIH) documented the rate of chronic HCV, using PCR and bDNA assays, and histologic (liver cell) damage in 60 anti-HCV positive individuals with chronic hepatitis (Shakil 1995). Tabled below are the results of the 60 patients equally divided into three groups: group 1: normal ALT levels; group 2: elevated ALT levels less than twice the normal range; and group 3: levels more than twice the normal range.


HCV Virologic & Histologic Confirmation of 60 Anti-HCV Volunteer Blood Donors

Group I
N=20
Group II
N=20
Group III
N=20
P
Baseline ALT42 (13-88) 80 (47-125) 125 (40-308) <.0001
Virology
HCV RNA PCR+13 (65%)19 (95%)19 (95) 0.0009
HCV RNA bDNA+12 (60%)18 (90%)17 (75%)0.091
Histology0.018
Normal 300
Nonspec. Changes300
Chronic Hepatitis
Mild8169
Moderate639
Severe011
Active Cirrhosis00

(Shakil 1995)


The presence of viremia (HCV RNA in blood) in all groups did not correlate with age, route of transmission, or duration of infection. Nonetheless, those who were HCV RNA-negative were more likely to have persistently normal ALT levels (78%) compared to those who were HCV RNA-positive (20%). Likewise, most of those who were HCV RNA-negative had either normal liver histologic findings or only mild changes (Shakil 1995).

Some individuals (~15%) who test HCV RNA-positive during acute or post-acute HCV infection may eventually become undetectable and, conversely, some (~19%) who initially test HCV PCR-negative may become detectable at a later date. Villano and colleagues from Johns Hopkins studied HCV RNA patterns in 43 HCV seroconverters (documented by EIA-2 and RIBA-2) who were followed for 72 months (Villano 1999). Six (14%) patients had documented viral clearance (undetectable HCV RNA, <500 copies/mL) between one and two years; one patient was initially undetectable for HCV RNA and remained negative. Two of the patients who cleared virus had ~1 million copies/mL of virus. Factors associated with viral clearance were: white race (P = 0.004); jaundice (P = 0.003); and lower peak viral titers (P = 0.003).

The presence of HCV RNA did not always precede the development of antibodies: 48% had HCV RNA at their first seroconversion visit; 33% were HCV RNA-positive a median 3.8 months before seroconversion; and 19% were HCV RNA-detectable a median 15.3 months after estimated date of seroconversion. The fact that a person who may initially test qualitatively HCV RNA-negative (no detection of HVC in serum) but later become positive suggests that "in clinical practice, virologic outcome must be determined by long-term follow-up, not a single HCV RNA level" (Villano 1999).

One significant finding in this study deserves comment. Seventy-four percent of the anti-HCV-positive patients in this study (the majority with a history of intravenous drug use (IVDU)) had been evaluated by a physician during their seroconversion intervals, yet only a few were recognized as having HCV or were screened for it. In this case, one cannot say that hepatitis was not detected because of limited access to health care. Even though HCV does not present with severe symptoms, this routine failure to diagnosis HCV in patients known to be at high risk indicates a striking lack of awareness by health care providers about HCV and its epidemiology.


Chronic Infection

Data from various studies indicate that 75-85% of individuals with acute HCV infection will become chronically infected (MJ Alter 1992; Shakil 1995; Villano 1999). The reason for such a high rate of chronicity is not completely understood. Some studies suggest that HCV persistence is related to the high mutation rate of HCV and the continual turnover of complex viral quasispecies that are able to evade the immune response of the host (Tsai 1998; Ray 1999). Farci and colleagues from the University of Cagliari and Robert Purcell's NIH laboratory recently published data which suggest that resolution of acute hepatitis is associated with relative evolutionary stasis of quasispecies, but progression to chronicity is correlated with genetic evolution of HCV (Farci 2000).

Only 60% to 70% of chronically infected individuals will have persistent or fluctuating ALT elevations; the other 30% to 40% will have normal ALT levels throughout the course of their infection. Two studies, one by Shakil and colleagues, the other by Pastore and colleagues have documented that relatively low (13-135) or normal ALT levels during acute infection were prognostic indicators predicting loss of HCV infection (Pastore 1985; Shakil 1995). In at least four other natural history studies, however, ALT levels were not found to be predictive of clearance (Mattsson 1989; Esteban 1991; MJ Alter 1992; Villano 1999). Except for the Villano study mentioned above, which noted that whites had a higher rate of clearance than blacks (80% of the subjects were black), and a small Swedish study (N = 37) by Mattsson that documented an increased rate of clearance among patients under 30 years old, no other major natural history studies have found any prognostic factors for disease clearance (Mattsson 1989; Villano 1999). In 2000, it is still a guessing game as to who will develop chronic infection. According to Juan Ignacio Esteban, "No clinical, biochemical or virological feature can predict the outcome of infection in a given individual" (Esteban 1999).

A liver biopsy gives the most accurate information about the degree of liver injury associated with HCV infection. There are many complex and detailed staging and scoring systems for liver biopsies (e.g., Knodell score, METAVIR fibrosis score).

According to Leonard Seeff, natural history studies have used one of three evaluation strategies (Seeff 1997, 2000a):

One of the most important prospective natural history studies, the NIH Prospective Study of HCV-Infected Donors, was recently published (HJ Alter 1997). It included 280 HCV RNA- positive blood donors followed for a median of 20 years. ALT levels were repeatedly normal in 17%; 45% had <2X the upper limit of normal; and 38% had a least one reading 5X the upper limit. Liver biopsies were performed on 81 of 280 patients, and a probable date of exposure could be ascertained in 74 of the 81. The chart below represents biopsy findings according to time from exposure:

Only 1.3% had histologic evidence of severe hepatitis and cirrhosis following a mean interval of 18 years from time of exposure. According to Harvey Alter, "Liver-related mortality or severe morbidity is less than 10% in the first two decades after infection." (Alter 1997)

Koretz and colleagues from UCLA documented a more progressive clinical course in their study of 80 recipients of HCV transfused blood who were followed for 14 years (Koretz 1993). After 16 years of known infection, 10% had HCV-related symptoms; 18-20% had biopsy-proven cirrhosis; 1.3% developed hepatocellular carcinoma (HCC; liver cancer); and 2.5% died of liver-related complication.

Cohort studies of chronic HCV patients referred to liver-oriented tertiary-care centers suggest progressive HCV disease. Tong and colleagues followed 131 patients with HCV for approximately 22 years: mean age at transfusion was 35 years, and at time of evaluation, the mean age was 57 years (Tong 1995). After about four years of follow-up, over 67% were experiencing HCV-related symptoms (specifically fatigue); 46% had biopsy-proven cirrhosis; 10.6% had developed HCC; and 15.3 % had died of liver-related deaths. The accompanying chart documents time to hepatic event:

Two significant retrospective natural history studies were recently published reporting the longest follow-up yet of well-characterized HCV infected cohorts (Kenny-Walsh 1999; Seeff 2000b). The first, by Kenny-Walsh and colleagues, documents the clinical course of HCV in a group of 376 HCV RNA-positive Irish women who had been infected during 1977­1978 with a batch of HCV-contaminated anti-D immune globulin (Kenny-Walsh 1999). The mean age of the women at time of infection was ~28 years, and after 17 years of living with HCV, the mean age of at screening/biopsy was 45 years. None had received any anti-HCV treatment. HCV-related symptoms, histologic grade of hepatic inflamation, and stage of fibrosis for the 363 women who underwent biopsies are documented below:


Symptoms and Histologic Findings in Irish Women ~17 Years Post HCV-infection
VariableNo. of WomenALT Level (U/liter)


MedianRange
Documented Symptoms (N=376)
  Reported >1 Symptoms304 (81%)

  Fatigue248 (66%)

  Arthralgia or Myalgia143 (38%)

  Anxiety or Depression 60 (16%)

  Right-upper-quadrant Pain23 (6%)

  Rashes19 (6%)

Histologic Findings (N=363)
  Grade of Inflammation
  07 (2%) 2411-66
  1-3150 (41%)3710-61
  4-8190 (52%)4610-232
  9-1816 (4%)8034-381*
  Stage of Fibrosis
  No Fibrosis177 (49%)3510-198
  Periorbital or Portal Fibrosis124 (34%)4610-261
  Portal-portal Bridging Fibrosis 36 (10%)5315-381
  Portal-central Bridging 19 (5%)100**34-232
  Probable or Definite Cirrhosis 7 (2%)4210-381
* Correlation between grade of inflamation and ALT levels (R=0.23, P<0.001)
**Correlation between stage of fibrosis ALT levels (R=0.30, P<0.001)
(Kenny-Walsh 1999)


Compared to other studies, this study appears to document a slower progressive course of HCV infection. After 17 years of infection, no fibrosis was documented in nearly half of the women, and cirrhosis in only 2%. Another study from Germany of 152 women infected with HCV-contaminated RH0(D) immune globulin documented a similar clinical course (Muller 1996). After 15 years, none of the women were found to have chronic active hepatitis or cirrhosis. There are many speculations as to why disease in this cohort of women was so indolent: 1) disease in women is less progressive than in men; confirmed by Poynard and colleagues (Poynard 1997); 2) patients infected at a younger age fare better than older ones; confirmed by Tong and colleagues as well as Poynard (Tong 1995; Poynard 1997); and 3) the small amount of the infecting dose of anti-D immune globulin (versus that of a blood transfusion) may have played a role (Kenny-Walsh 1999).

The 45-year HCV natural history study of 8,568 military recruits by Seeff and colleagues reports the earliest confirmed detection of HCV in the United States and has the longest follow-up of any study published to date (Seeff 2000b). Originally, 8,568 military recruits were tested for group A streptococcal infection and acute rheumatic fever between 1948 and 1954. After initial blood tests, samples were frozen and saved for 45 years. Seventeen (0.2%) individuals tested positive for HCV antibodies on EIA-3 and RIBA-3. While 17 HCV-positive patients followed in a natural history study may seem small, it's the HCV-negative control group of over 8,000 individuals (99% men) that makes this study important. Records tracking 45 years of liver abnormalities, disease, and death (using the National Death Index Plus service) as well as age, sex, race, chart review, and cause-specific mortality from death certificates were available from the Veterans Affairs' computer files.

A vast majority of the recruits were younger than 25 years of age at the original blood draw. Approximately 90%, 10%, and 0.5% were white, black and Asian, respectively. HCV infection in blacks was significantly higher than whites: 1.8% compared to 0.07% (RR, 25.9; CI, 8.4 to 80.0). The mean age of the surviving cohort, as of January 1997, was 64.8 years (95% were between 60 and 69 years of age). Eleven of the seventeen (65%) HCV-infected men were HCV RNA-positive; all but one had genotype 1b.


Death from All Causes & Liver-disease-related Mortality
after 45 Years Follow-up in 8,568 Military Recruits
EventHCV+ Group (N=17)HCV-Group
( N=8,551)
RR (95% CI) Ethnically Adjusted
Liver Disease2 (11.8%)205 (2.4%)3.56 (0.94-13.52)
All Deaths7 (41%)2226 (26%)1.48 (0.8-2.6)*
Mean Age at Death56.5 years54.2 yearsNS
Liver Disease-related Death1 (16.7%)119/1890 (6.3%)
Death from Liver Cancer09 (0.5%)
(Seeff 2000b)


Of the seven deaths in the HCV-positive group, only one was due to liver disease. The fact that the event rate was so low in the HCV-positive group after four decades, and that there was little difference in mortality between the groups, leaves one to believe that HCV is a less progressive disease than is currently thought. According to Leonard Seeff, long-term natural history data have revealed that only 15% to 20% of HCV-infected persons will eventually develop progressive to potentially serious end-stage liver disease (namely cirrhosis) and that the remainder will die of causes other than liver disease (Seeff 2000a).

Prognostic Factors for Fibrosis Progression:
Good News for the Non-alcohol-imbibing Woman Infected with HCV Before She Was 40

A seminal natural history from France by Poynard and colleagues documents host factors, rather than virologic factors, as risks for fibrosis progression in untreated HCV-positive patients (Poynard 1997). Some 2,235 patients were selected from three well-characterized cohorts: Observatoire de l'Hépatite C (OBSVIRC); Cohorte Hépatite C Pitié-Salpêtrière (DOSVIRC); and the METAVIR. All patients underwent liver biopsy, and the METAVIR1 scoring system was used to grade the stage of fibrosis. Nine factors were assessed for effect on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; HCV genotype; HCV viremia; method of infection; and histologic activity grade. Fibrosis progression was defined as the ratio between fibrosis stage in METAVIR units and the estimated duration of infection. (For example, for a patient with stage 2 fibrosis who had been HCV-infected for eight years, the fibrosis progression rate would be 0.25 fibrosis units per year.)

The mean and median rate of fibrosis progression per year for the 1,157 patients whose duration of infection was known was 0.252 (95% CI, 0.227-0.277) and 0.131 (95% CI, 0.125-0.143), respectively. At this rate the median time to cirrhosis was estimated as 30 years (range: 28-32 years); 33% had a median time of 20 years and 31% will never progress or will not progress for at least 50 years. Out of the nine factors assessed, three had highly significantly correlation with disease progression: gender, alcohol consumption, and age at infection. Interestingly, amount of HCV RNA and viral genotype (i.e., 1b) did not correlate significantly with disease progression. (See "HCV Treatments" chapter, where both are significant prognostic factors for success of treatment.)


Multivariate Analysis of the Three Significant Risk Factors for Fibrosis Progression in 1,038 Patients
FactorRelative Risk95% CIfor Fibrosis Progression in 1,038 Patients
Age at Infection (>40 years)1.071.06-1.08<0.0001
Male Sex2.661.90-3.72<0.0001
Alcohol Consumption (>50 grams/day)1.491.18-3.03<0.008
(Poynard 1997)
Association between Rate of Fibrosis Progression and Age at Infection
Age GroupRate of Increase Fibrosis
31-40 Years vs. 21-40 Years 31%
41-50 Years vs. 31-4145%
>50 Years vs. 41-5067%
(Poynard 1997)


Varying prognostic factors predict a benign course of HCV for some and a severe one for others. A female infected before the age of 40 who drinks <50 grams (equals 5 glasses) of alcohol per day has an expected time to cirrhosis of 42 years compared to 15 years for a man infected after the age of 40 who drinks more than 50 grams of alcohol per day.


Selected Prognostic Factors for Disease Progression and Survival

Age (Tremolada 1992; Tong 1995; Fatovitch 1997; Poynard 1997; Neiderau 1998; Deuffic 1999); male gender (Poynard 1997; Deuffic 1999; Khan 2000); and increased alcohol intake (Donato 1997; Fattovitch 1997; Poynard 1997; Rudot-Thoraval 1997; Neiderau 1998; Wiley 1998) have been documented by many (but not all) as highly prognostic factors for HCV-related liver disease progression. However, other important prognostic factors for advanced disease progression have been less consistently documented in published natural history studies. Mode of HCV transmission: Blood transfusion vs. IVDU vs. Sporadic Cases.

Two published studies have suggested that infection through blood transfusion (BT) (compared to infection via IVDU) is a highly significant prognostic factor for liver disease progression (Rudot-Thoraval 1997; Gordon 1998). Gordon and colleagues studied the clinical course of 627 chronically HCV-infected patients: 282 (45%) were BT recipients, 262 (42%) were infected via IVDU, and 83 (13%) were without known risk factors. The median estimated disease duration for all patients was 21 years (+/- 9.53 years) and the duration of follow-up ranged from 1 to 25 years. Liver histology was available on 463 patients. Cirrhosis was determined in 173/463 (37%): 118/173 (68%) were BT recipients; 40/173 (23%) were infected via IVDU (P<0.001). Below is a breakdown of those who had HCC, cirrhosis, or no cirrhosis:

Unlike the Poynard study (discussed above), in Gordon's patients, age or estimated disease duration did not predict risk of liver failure in the multivariate analysis (Poynard 1997; Gordon 1998). Rudot-Thoraval and colleagues from France also noted an increased prevalence of cirrhosis in BT patients in their survey of 6,664 chronic HCV patients (Rudot-Thoraval 1997).

Of 2,500 patients with known duration of HCV infection, the prevalence of cirrhosis for BT recipients was 22.8% compared to 5.8% for those infected via IVDU (P<0.02; OR = 0.61; 95% CI, 0.40-0.92).

"Sporadic cases" are HCV infections without identified risk factors. Fattovitch and colleagues from Italy noted that sporadic cases with compensated cirrhosis had poorer survival compared with those infected via BT or IVDU (Fattovitch 1997). Likewise, Khan and colleagues from Australia recently reported that sporadic cases were at significantly higher risk for cirrhosis, HCC, and liver transplantation or death (Khan 2000). The complete opposite was seen in a German HCV natural history study conducted by Hopf and colleagues (Hopf 1990). Finally, Poynard did not find any of these modes of transmission to be a significant prognostic factor in his study (Poynard 1997).

Abnormalities in Laboratory Values: Albumin and Bilirubin
In the 455 Australian HCV patients from the Khan study, serum albumin (a protein made by the liver that is responsible for maintaining fluid inside blood vessels) concentrations of <30 g/L at entry was associated with an 85% chance of liver-related complications at five years and a three-year mortality of 70% (Khan 2000). Gordon also noted that low serum albumin (3.2 g/L compared to 4.2 g/L) was an independent predictor of subsequent hepatic decompensation (P = 0.001; OR = 0.054; 95% CI, 0.030-0.099) (Gordon 1998). Similar findings were noted years earlier in two HCV natural history studies conducted by Fattovich and colleagues and Yano and colleagues (Yano 1996; Fattovich 1997). The deleterious effects resulting from low serum albumin levels in late-stage HCV patients prompted Hirsch and Wright to write in a Hepatology editorial:

End-stage disease from hepatitis C is one of the leading indications for liver transplantation in the United States. Currently, listing for transplantation requires significant abnormalities in at least 2 of 5 elements of the Child-Pugh [cirrhosis] classification. This may merit reassessment if the dramatic predictive value of the serum albumin alone can be validated in other large, prospective studies. (Hirsch 2000)

To a lesser extent, elevated bilirubin has been noted as a risk factor for HCV-related liver disease progression (Fattovitch 1997; Khan 2000). In their 1997 study of 384 Italians with cirrhosis, Fattovich and colleagues found that abnormally high bilirubin was a predictor of poorer survival (Fattovitch 1997). Those with bilirubin <17 mmo/L had five- and ten-year survival probabilities of 96% and 86% respectively, compared with 81% and 67% for those with bilirubin >17-<51 mmo/L (P = 0.0001).

Prolonged prothrombin time (decreased duration of blood coagulation) and decreased platelet count have been documented as significant predictors of disease progression in later-stage patients (Fatovitch 1997; Gordon 1998).


Coinfection with HAV, HBV, and HIV

(See "Hepatitis & HIV Coinfection" chapter for more details)

HCV patients who acquire HAV have been found to have a substantial risk for fulminant hepatic failure2 and death (Vento 1998). In an Italian HCV natural history study, 432 patients were tested thrice yearly for the development of HAV antibodies. Seventeen HCV patients (three with cirrhosis) subsequently acquired HAV infection. Ten of the patients had an uncomplicated course of HAV, but seven developed fulminant hepatic failure, and six died. There was no apparent difference in degree of baseline liver damage, yet the development of HAV posed a 41% chance of fulminant hepatitis and a 35% chance of death (Vento 1998).

Vento concludes that all HCV-infected individuals should be vaccinated for HAV, saying, "Chronic carriers of HCV who are at risk for HAV infection should be vaccinated against HAV, since superinfection with this virus may place them at risk for severe, life-threatening acute liver damage" (Vento 1998). In a subsequent Lancet editorial, Marina Berenguer and Teresa Wright agree that HAV vaccination may be warranted, but believe that Vento's results need confirmation and that a cost-benefit analysis is essential before implementing such a policy worldwide (Berenguer 1998).

HCV patients with HBV have been found to have an increased risk for cirrhosis (Roudot-Thoraval 1997; Cacciola 1999). Cacciola and colleagues from Italy tested for the presence of HBV DNA in a cohort of 200 chronically HCV-infected individuals. Sixty-six (33%) were found to have HBV sequences. Of these 66 patients, 22 (33%) had evidence of cirrhosis compared to 26 (19%) of 134 HCV-positive/HBV-negative patients (P = 0.04). This study confirmed the results of a French study of 5,786 histologically HCV-diagnosed patients (Roudot-Thoraval 1997). Cirrhosis at liver biopsy was found in 24.6% of patients positive for HBV surface antigens compared to 21.1% in those who were HBV-antigen-negative (P<0.001; OR = 1.99; 95% CI, 1.40-2.82).

Studies of people coinfected with HCV and HIV have reported that, while the progression of HIV disease is not changed by HCV, HCV infection progresses more rapidly in people with HIV. When matched for other variables, on average, people who are HIV-positive have higher levels of HCV RNA than HIV-negative people (Eyster 1993, 1994; Cribier 1995). It is important to note that a majority of natural history coinfection studies were conducted before the advent and widespread use of potent antiretroviral therapy. With control of HIV viremia and better immune status, the natural history of HCV in these patients will likely change. In immunocompetent HIV-positive individuals, HCV may replace certain opportunistic infections (i.e., Pneumocystis carinii pneumonia, mycobacterium avium complex and cytomegalovirus retinitis) as a leading cause of increased morbidity and mortality.

Benhamou and colleagues from Theiry Poynard's group in France have recently reported on fibrosis progression in their well-characterized coinfected DOSVIRC cohort (Benhamou 1999a, 1999b). Low CD4 count (<200 cells/mm3), alcohol consumption of more than 50 grams/day, and age at HCV infection (>25 years old) were shown to be associated with an increased liver fibrosis progression rate (Benhamou 1999b). In a linear progression model, there was little difference in time from infection to cirrhosis between the HCV+/HIV+ patients and the matched HCV+/HIV- groups if those with coinfection who had a T-cell count of >200 and drank <50 grams/day of alcohol. The accompanying chart documents time to cirrhosis:


Virologic Determinants

Quantitative HCV RNA levels do not appear to affect the clinical course of HCV-infected individuals who are naive to treatment. Lau and colleagues found no difference in serum HCV RNA levels between patients with chronic persistent hepatitis, chronic active hepatitis, or cirrhosis (Lau 1993). These finding were confirmed in larger natural history studies (Poynard 1997; DeMoliner 1998).

There is considerable debate as to whether certain HCV genotypes, especially 1b, put patients at increased risk for disease progression. Kabayashi and colleagues found that the deterioration of liver histology during a median 9.6 years of follow-up was more common in patients with genotype 1 (68%) -- namely 1b -- than in those with genotype 2 (41.7%) (P<0.01) (Kobayashi 1996). Likewise, an advanced stage of liver histology was more common in the genotype 1 patients (63%) compared to those with genotype 2 (38.9%) (P<0.05). An earlier, smaller study conducted in the United Kingdom also noted that those with genotype 1 had a far more progressive histologic disease than those with genotypes 2, 3, or 4 (Dusheiko 1994). However, difference in disease outcome according to genotype has not been verified in most treatment-naive natural history studies after 1996 (Poynard 1997; Serfaty 1997; Neiderau 1998; Khan 2000). Finally, in interviews conducted with leading hepatology researchers and clinicians, none believe that genotype independently has an effect on the natural history of hepatitis in patients naive to therapy (see "Current Opinions and Controversies" chapter).

  1. The METAVIR scoring system grades the stage of fibrosis on a five point scale: 0 = no fibrosis; 1 = portal fibrosis without septa; 2 = few septa; 3 = numerous septa without cirrhosis; 4 = cirrhosis (The METAVIR Cooperative Group 1994). Histologic activity (intensity of necroinflammatory lesion) is graded on a four point scale: A0 = no histologic activity; A1 = mild activity; A2 = moderate activity; A3= severe activity.
  2. Fulminant hepatic failure is the development of severe liver injury with hepatic encephalopathy (HE). HE is a condition where the brain function is impaired by the presence of toxic substances, absorbed from the colon, which are normally removed and detoxified by the liver.


References

Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 325:1325-9, 1991.
Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology Sep:26(3 Suppl 1):29S-33S, 1997.
Alter MJ, Margoliis HS, Krawczynksi K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327:1899-905, 1992.
Benhamou Y, Bochet M, Dimartino V, et al. Anti-Protease Inhibitor Therapy Decreases The Liver Fibrosis Progression Rate In HIV-HCV Coinfected Patients [abstract]. Hepatology 30:362A, 1999.
Benhamou Y, Bochet M, DiMartino V, et al. Liver Fibrosis Progression in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients. Hepatology 30:1054-58, 1999.
Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 25: 211-15, 1997.
Berenguer A, Wright TL. Are HCV-infected individuals candidates for hepatitis A vaccine [editorial]? Lancet 351:924-25, 1998
Cacciola I, Pollicino T, Squadrito G, et a. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22-6, 1999. De Moliner L, Pontisso P, De Salvo G L, et sl. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 42: 856-860, 1998.
Deuffic S, Buffat L, Poynard T, et al. Modeling the hepatitis C virus epidemic in France. Hepatology 29:1596-601, 2000.
Di Biscelie AM, Roggendorf M, Durkop L, et al. Long-term clinical and histopatological follow-up chronic posttansfusion hepatitis. Hepatology 14:969-74, 1991.
Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 31:1014- 18, 2000.
Dienstag JL. Non-A, non-B hepatitis. I: recognition, epidemiology, and clinical featurs. Gastroenterology 85:439-62, 1983.
Dienstag JL. The natural history of chronic hepatitis C and what should we do about it? Gastroenterology 112:651-5, 1997.
Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy. Hepatology 26:579-584, 1997.
Dusheiko G, Weiss HS, Brown, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19:13-18, 1994.
Esteban JI, Gonzalez A, Hernandez JM, et al. Evaluation of antibodies to hepatitis C virus in a study of transfussion-associated hepatitis. N Engl J Med 323:1107-12, 1990.
Esteban JI, Cordoba J, Saulead S. The picture of acute and chronic hepatitis C. In Reesink HW, ed. Hepatitis C Virus. Current Studies in Hematology and Blood Transfusion. Basel: Karger, 102-118, 1998.
Esteban JI. Treatment of acute hepatitis C. In Arroyo V, ed. Treatment of Liver Disease. Barcelona: Masson, 279-86, 1999.
Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 325:98-104, 1991.
Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the viral evolution of the viral quasispecies. Science 288:339-44, 2000.
Fattovitch G, Giustina G, Degos F, et al. Morbidity and mortality in compansated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463-472, 1997.
Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a fucntion of mode of transmission. Hepatology 28:562-7, 1998.
Hirsch KR, Wright TL. "Silent killer" or benign disease. The dilemma of hepatitis C virus outcomes [editorial]. Hepatology 31:536-37, 2000.
Hopf U, Moller B, Kuther D, et al. Long-term follow-up of post-transfusion and sporatic chronic hepatitis non-A, non-B and frequency of circulating antibodies to heaptitis C virus (HCV). J Hepatol 10:69-76, 1990.
Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 340:1228-33, 1999.
Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complication? Hepatology 31:513-20, 2000.
Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 119:110-5, 1993.
Koretz RL, Brezina M, Polito AJ, et al. Non-A, non-B posttransfusion hepatitis: comparing C and non-C hepatitis. Hepatology 17:361-5, 1993.
Lau JYN, Davis G, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501-04, 1993.
Mattsson L, Weiland O, Glaumann H. Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up--a comparison. Liver 9:120-7, 1989. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28:1687-95, 1998.
Pastore G, Monno L, Santantonio T, et al. Monophasic and polyphasic pattern of alanine aminotransferase in acute non-A, non-B hepatitis. Clinical and prognostic implications. Hepatogastroenterology 32:155-8, 1985.
Poynard T, Bedossa P, Opolon P. Natual history of liver fibrosis progression in patients with chronic heaptitis C. Lancet 349:825-32, 1997.
Ray SC, Wang YM, Laeyendecker O, et al. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73:2938-46, 1999.
Roudot-Thoraval F, Bastie A, Pawlotsky J-M, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 26:485-490, 1997.
Seefff LB. Natural history of hepatitis C. Hepatology 26(3 Suppl 1):21S-28S, 1997.
Seeff LB. The natural history of hepatitis C -- A quandary [editorial]. Hepatology 28:1710-12, 1998.
Seeff LB. Natural history of hepatitis C. In: Liang TJ, moderator. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 132:299-300, 2000.
Seeff LB, Miller R, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132:105-11, 2000.
Serfaty L, Chazouilleres O, Poujol-Robert A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-controlled study. Hepatology 26:776-779, 1997.
Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 123:330-7, 1995.
Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-66, 1995.
Tremolada F, Casarin C, Tagger A, et al. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med 114:277-81, 1991.
Tsai SL, Chen YM, Chen MH, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 115:954-65, 1998.
Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A vrus superinfection in patients with chronic hepatitis C. N Engl J Med 338:286-90, 1998.
Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908-14, 1999.
Wiley TE, McCarthy M, Breida L, et al. Impact of alcohol on histological and clinical progression on hepatitis C infection. Hepatology 28:805-09, 1998.
Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of hepatitis C. Hepatology 23:1334-40, 1996.
Back | Next
Table of Contents




This article was provided by Treatment Action Group. It is a part of the publication The Hepatitis Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art1699.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.